Machida H, Tokunaga H, Matsuo K, et al. - The efficacy and safety of neoadjuvant chemotherapy with carboplatin/paclitaxel followed by interval debulking surgery (NACT-IDS) vs primary debulking surgery plus postoperative chemotherapy (PDS) for advanced ovarian cancer were examined. An Expert Panel of the Japan Society of Gynecologic Oncology Ovarian Cancer Committee conducted a comprehensive systematic review and meta-analysis. Inclusion of four phase III randomized clinical trials was done after screening 333 studies; these comprised 1,692 women (847 receiving NACT-IDS and 845 receiving PDS). Outcomes suggested that NACT-IDS with carboplatin and paclitaxel results in significantly lowering of perioperative complications and mortality by 70%–80% while having no negative effect on the survival of women with advanced ovarian cancer when compared with PDS.